Lucille is a Senior Associate in the London office and focuses primarily on therapeutics and healthcare IT. Prior to joining F-Prime in 2018, Lucille was a Junior Engagement Manager in McKinsey’s Private Equity and Pharmaceutical practices in London. During her time at McKinsey, she was also an Analytics Associate at QuantumBlack working on AI and Machine Leaning projects for pharmaceutical clients.
Lucille completed her clinical foundation and internal medicine training at the National Hospital for Neurology and Neurosurgery, UCLH, Imperial College, and Barts Foundation NHS Trusts. Lucille holds a BSc in Clinical Neuroscience and an MBChB with distinction from the University of Glasgow.
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle Therapeutics was acquired by Angelini Pharma in January 2021.
Owkin combines life-science and machine learning expertise to make drug development and clinical trial design more targeted and more cost effective. Owkin’s machine learning algorithms create models that predict disease evolution and treatment outcomes. These predictive models are implemented in clinical trials for enhanced analysis, surrogate endpoints, patient stratification, patient selection, and high-value subgroup identification. The impact of this research is faster discovery of better treatments at a lower cost. Learn more at www.owkin.com.